SI2558435T1 - Ortorombični kristalnični ingenol mebutat - Google Patents

Ortorombični kristalnični ingenol mebutat

Info

Publication number
SI2558435T1
SI2558435T1 SI201131237T SI201131237T SI2558435T1 SI 2558435 T1 SI2558435 T1 SI 2558435T1 SI 201131237 T SI201131237 T SI 201131237T SI 201131237 T SI201131237 T SI 201131237T SI 2558435 T1 SI2558435 T1 SI 2558435T1
Authority
SI
Slovenia
Prior art keywords
ingenol mebutate
orthorhombic crystalline
crystalline ingenol
orthorhombic
mebutate
Prior art date
Application number
SI201131237T
Other languages
English (en)
Inventor
Steven Martin Ogbourne
Original Assignee
Leo Pharma A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44318125&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2558435(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Leo Pharma A/S filed Critical Leo Pharma A/S
Publication of SI2558435T1 publication Critical patent/SI2558435T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/533Monocarboxylic acid esters having only one carbon-to-carbon double bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00Preparation of carboxylic acid esters
    • C07C67/48Separation; Purification; Stabilisation; Use of additives
    • C07C67/52Separation; Purification; Stabilisation; Use of additives by change in the physical state, e.g. crystallisation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/12Keratolytics, e.g. wart or anti-corn preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0034Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00Systems containing at least three condensed rings
    • C07C2603/56Ring systems containing bridged rings
    • C07C2603/86Ring systems containing bridged rings containing four rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Liquid Crystal Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Medicinal Preparation (AREA)
SI201131237T 2010-04-16 2011-04-18 Ortorombični kristalnični ingenol mebutat SI2558435T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32503210P 2010-04-16 2010-04-16
PCT/IB2011/001277 WO2011128780A1 (en) 2010-04-16 2011-04-18 Crystalline ingenol mebutate
EP11731076.3A EP2558435B1 (en) 2010-04-16 2011-04-18 Orthorhombic crystalline ingenol mebutate

Publications (1)

Publication Number Publication Date
SI2558435T1 true SI2558435T1 (sl) 2017-10-30

Family

ID=44318125

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201131237T SI2558435T1 (sl) 2010-04-16 2011-04-18 Ortorombični kristalnični ingenol mebutat

Country Status (24)

Country Link
US (2) US8653133B2 (sl)
EP (1) EP2558435B1 (sl)
JP (1) JP2013525300A (sl)
KR (1) KR20130091647A (sl)
CN (1) CN102844294A (sl)
AU (1) AU2011241893B2 (sl)
BR (1) BR112012026420A2 (sl)
CA (1) CA2796044A1 (sl)
CY (1) CY1119394T1 (sl)
DK (1) DK2558435T3 (sl)
ES (1) ES2633814T3 (sl)
HR (1) HRP20171072T1 (sl)
HU (1) HUE034138T2 (sl)
IL (1) IL222265A (sl)
LT (1) LT2558435T (sl)
MX (1) MX338480B (sl)
NZ (1) NZ603567A (sl)
PL (1) PL2558435T3 (sl)
PT (1) PT2558435T (sl)
RS (1) RS56337B1 (sl)
RU (1) RU2572618C2 (sl)
SI (1) SI2558435T1 (sl)
WO (1) WO2011128780A1 (sl)
ZA (1) ZA201207409B (sl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10143638B2 (en) * 2009-02-13 2018-12-04 Leo Laboratories Limited Method of treating skin with ingenol mebutate
JP2013525300A (ja) 2010-04-16 2013-06-20 レオ ファーマ アクティーゼルスカブ 結晶性インゲノールメブテート
PT2595948T (pt) * 2010-07-20 2019-11-12 Leo Laboratories Ltd Um método de produção de ingenol-3-angelato
US9402823B2 (en) 2010-12-17 2016-08-02 Leo Laboratories Limited Ingenols for treating seborrheic keratosis
WO2012176015A1 (en) * 2011-06-24 2012-12-27 Leo Pharma A/S Methods for treating uv-damaged skin and scc tumors and for removing tattoos with topical ingenol mebutate
US20140350101A1 (en) * 2011-12-12 2014-11-27 Leo Laboratories Limited Gel compositions
WO2013088379A1 (en) * 2011-12-12 2013-06-20 Leo Laboratories Limited A topical composition comprising an ingenol derivative and a surfactant-cosolvent mixture
EP2790669A1 (en) 2011-12-12 2014-10-22 Leo Laboratories Limited A topical composition comprising an ingenol derivative and an oily solvent
WO2013110756A1 (en) * 2012-01-26 2013-08-01 Leo Pharma A/S Ingenol mebutate in combination with cryotherapy for the treatment of actinic keratosis
US20130251782A1 (en) * 2012-03-22 2013-09-26 Leo Laboratories Limited Topical application of ingenol mebutate with occlusion
WO2013182688A1 (en) * 2012-06-08 2013-12-12 Leo Laboratories Limited A topical gel composition comprising an ingenol derivative and a solvent mixture
GB201222403D0 (en) * 2012-12-12 2013-01-23 Leo Lab Ltd Gel compositions
WO2014090859A1 (en) * 2012-12-12 2014-06-19 Leo Laboratories Limited Gel compositions
GB201222405D0 (en) * 2012-12-12 2013-01-23 Leo Lab Ltd Gel compositions
GB201222406D0 (en) * 2012-12-12 2013-01-23 Leo Lab Ltd Gel compositions
AU2014100280B4 (en) * 2014-03-24 2015-01-15 Leo Pharma A/S A method of treating skin lesions
US9526714B2 (en) 2014-03-24 2016-12-27 Leo Laboratories Limited Method for treating skin lesions with ingenol mebutate
CN107510651A (zh) * 2016-06-17 2017-12-26 王成 一种小分子免疫药物的纳米靶向制剂制备及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO864097A0 (en) 1997-08-19 1997-09-11 Peplin Pty Ltd Anti-cancer compounds
US20060052951A1 (en) * 2004-05-07 2006-03-09 Yaffe Michael B Methods and compositions for cancer treatment relating to BRCA1 BRCT domain recognition of phosphorylated BACH1
RU2438689C9 (ru) * 2005-06-28 2012-03-10 Амазония Фитомедикаментус ЛТДА Активная фракция экстракта млечного сока растения семейства euphorbiaceae, способ ее получения, композиция на ее основе (варианты) и способ лечения заболеваний, связанных с пролиферацией клеток (варианты)
CA2629337A1 (en) * 2005-11-14 2007-05-18 Peplin Research Pty Ltd Use of angeloyl-substituted ingenanes in combination with other agents to treat cancer
BRPI0618926A2 (pt) * 2005-11-25 2011-09-13 Peplin Research Pty Ltd uso de um composto de ingenol ou um sal farmaceuticamente aceitável do mesmo
GB0525680D0 (en) 2005-12-16 2006-01-25 Peplin Ltd Therapeutic compositions
CN101742996B (zh) * 2007-04-30 2013-08-21 Leo实验室有限公司 巨大戟二萜醇在制备治疗非癌性皮肤损伤的药物中的用途
JP2013525300A (ja) 2010-04-16 2013-06-20 レオ ファーマ アクティーゼルスカブ 結晶性インゲノールメブテート

Also Published As

Publication number Publication date
AU2011241893B2 (en) 2014-11-06
ZA201207409B (en) 2014-06-25
DK2558435T3 (en) 2017-08-14
ES2633814T3 (es) 2017-09-25
US8653133B2 (en) 2014-02-18
MX2012011844A (es) 2012-11-30
LT2558435T (lt) 2017-07-25
US20110257262A1 (en) 2011-10-20
EP2558435B1 (en) 2017-06-07
PT2558435T (pt) 2017-07-24
WO2011128780A1 (en) 2011-10-20
MX338480B (es) 2016-04-19
PL2558435T3 (pl) 2017-10-31
JP2013525300A (ja) 2013-06-20
IL222265A (en) 2015-04-30
KR20130091647A (ko) 2013-08-19
EP2558435A1 (en) 2013-02-20
CA2796044A1 (en) 2011-10-20
NZ603567A (en) 2013-10-25
US20150025265A1 (en) 2015-01-22
HUE034138T2 (en) 2018-01-29
CN102844294A (zh) 2012-12-26
RU2012148720A (ru) 2014-05-27
RS56337B1 (sr) 2017-12-29
AU2011241893A1 (en) 2012-12-06
IL222265A0 (en) 2012-12-31
CY1119394T1 (el) 2018-02-14
BR112012026420A2 (pt) 2016-08-02
RU2572618C2 (ru) 2016-01-20
HRP20171072T1 (hr) 2017-10-06
US9440906B2 (en) 2016-09-13

Similar Documents

Publication Publication Date Title
RS56337B1 (sr) Ortorombični kristalni ingenol mebutat
GB201001075D0 (en) Crystalline forms
ZA201302989B (en) Threaded fastener
AP2013006790A0 (en) Substituted imidazopyradazines
HK1187248A1 (zh) 結晶納絡醇- 綴合物
TWM388577U (en) Multifunctional fastener
GB2485334B (en) Structure
PL2578595T3 (pl) Krystaliczna lewoizowalerylospiramycyna I
AU334252S (en) Pie timer
AP2013006922A0 (en) Substituted sodium-1H-pyrazole-5-olate
ZA201207343B (en) Fastener
EP2529618A4 (en) BAIT
GB2491770B (en) Molten-core retention structure
PL2627917T3 (pl) Łącznik z trzpieniem
HK1174229A1 (zh) 拉鏈
EG27093A (en) Combing element
PL2609342T3 (pl) Element mocujący
EP2591985A4 (en) PANEL ASSEMBLY STRUCTURE
GB201119674D0 (en) Fastener
GB201014672D0 (en) Photovoltaics
GB201002770D0 (en) Roof element
TWM402361U (en) Fastening element
GB201013488D0 (en) Structural element
EP2578109A4 (en) FIXING PIECE
TWM388864U (en) Fastener